Insmed’s TPIP Shows Strong Phase 2b Results in PAH, Phase 3 Planned for 2026

Highlights

• Insmed's TPIP met both primary and secondary endpoints in a 102-patient phase 2b study for PAH, showing a 35% reduction in PVR and a 35.5-meter walking distance improvement.
• These results exceeded prior efficacy benchmarks and boosted investor confidence, with shares surging over 27%.
• The company will engage the FDA to begin phase 3 trials, with plans to start trials for PAH in 2026 and PH-ILD before the end of 2025.
• TPIP could challenge United Therapeutics'Tyvaso DPI, which reached $1 billion in 2024 sales.
• Insmed also markets Arikayce, which generated $363 million in 2024.

Breakthrough Results Propel Phase 3 Preparations

Insmed has reported what it describes as "outstanding" phase 2b clinical results for its investigational therapy, treprostinil palmitil inhalation powder (TPIP), in patients with pulmonary arterial hypertension (PAH). The data has sparked enthusiasm among investors and the biopharmaceutical sector, with shares of Insmed jumping more than 27%, rising from $70 on Monday to around $89 on Tuesday morning.

TPIP is a prodrug version of United Therapeutics'treprostinil (marketed as Tyvaso) and is designed for administration via a capsule-based inhalation device. A prodrug is an inactive compound that metabolizes into an active drug within the body, potentially offering pharmacokinetic or delivery advantages.

Strong Phase 2b Efficacy Results

According to Insmed, its 102-patient phase 2b trial evaluating once-daily TPIP in PAH patients successfully met both primary and secondary endpoints. The treatment demonstrated "a 35% placebo-adjusted reduction in pulmonary vascular resistance (PVR) from baseline and a 35.5-meter improvement in a six-minute walking distance."

Both endpoints—PVR and six-minute walking distance—are pivotal in evaluating treatment efficacy for PAH, a progressive and rare cardiopulmonary disease that leads to increased blood pressure in pulmonary arteries. The condition is marked by symptoms such as fatigue and shortness of breath and can result in high morbidity and mortality.

Insmed had indicated earlier that "a 20% PVR improvement and a 15-to-20-meter increase in the walking test could be seen as a clear win." These benchmarks are in line with what many experts, including Jefferies analyst Kelly Shi, Ph.D., had suggested could support a shift in physician preference from Tyvaso to TPIP.

Path Forward: Regulatory and Clinical Plans

Following this phase 2b success, Insmed plans to "immediately engage" with the U.S. Food and Drug Administration (FDA) to discuss phase 3 trial design. The company aims to initiate a phase 3 trial for PAH in early 2026 and begin another for pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025.

Gene Sullivan, M.D., Insmed’s Chief Product Strategy Officer, emphasized the broader impact of the findings: "The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy." He added, "These unprecedented Phase 2b results unequivocally demonstrate TPIP's potential to be a highly effective and well-tolerated once-daily prostanoid therapy for the treatment of PAH across disease severities and background treatment regimens."

Market Landscape and Competition

Should TPIP gain regulatory approval, it could intensify competition for United Therapeutics, which markets both Tyvaso and Tyvaso DPI, a dry powder inhalation version. United previously attempted to block Liquidia’s competing product, Yutrepia, through legal challenges against both Liquidia and the FDA. However, United's exclusivity for dry powder treprostinil expired in May, paving the way for Yutrepia's approval.

Tyvaso DPI generated $1 billion in sales in 2024, underscoring the commercial potential of inhaled PAH therapies. The original Tyvaso, approved in 2009, was the only treatment for PH-ILD until it received this expanded indication in 2021.

Insmed’s Broader Portfolio

Beyond TPIP, Insmed currently markets Arikayce, an inhaled antibiotic approved for use in combination therapy to treat Mycobacterium avium complex lung disease. In 2024, Arikayce brought in $363 million in revenue, providing a commercial base for Insmed’s ongoing pipeline development.